All In Biotech

Free tool

FAERS Monitor: Lipiodol

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 009190 or its brand name (Lipiodol, Ethiodized Oil). Reports on generic versions are filed under their own applications.

Reports

1,298

Serious

1,258

97% of reports

Hospitalization

286

Death reported

154

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • product use in unapproved indication294
  • off label use170
  • liver abscess73
  • pyrexia59
  • pulmonary embolism49
  • product use issue43
  • aspartate aminotransferase increased40
  • pancytopenia36
  • alanine aminotransferase increased35
  • disease progression33
  • overdose31
  • hepatic artery stenosis30
  • cerebral artery embolism28
  • maternal exposure before pregnancy28
  • hypothyroidism27

Reports by year received

View as table
YearReports
20042
20066
20073
20083
20098
20107
201129
201226
201325
201425
201564
201682
2017109
2018123
201997
202076
202164
202267
202386
2024144
2025109
2026143

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,861 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
hepatic artery stenosisSignal304865.83247.5108,532
cerebral artery embolismSignal28381.3263.210,009
liver abscessSignal73373.0297.726,119
maternal exposure before pregnancySignal2866.746.21,740
product use in unapproved indicationSignal29419.217.45,121
hypothyroidismSignal2713.79.4306
aspartate aminotransferase increasedSignal4012.29.0401
pancytopeniaSignal3610.47.6299
alanine aminotransferase increasedSignal359.26.7250
pulmonary embolismSignal498.46.4311
disease progressionSignal334.53.287
product use issueSignal433.72.883
off label useSignal1703.12.7257
pyrexiaSignal592.82.266
overdoseSignal312.31.622

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.